611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Obesity to Blame for Almost 1 in 25 Cancers WorldwideEczema Can Drive People to Thoughts of Suicide: StudyHispanics Bear Brunt of Exposure to Workplace Hazards: Study'Experience to Share': Facebook Page Helps Families Hit by Polio-Like IllnessHospitalizations Rising Among the HomelessAnimal, Bug Bites a Billion-Dollar BurdenHidden Dangers in DustCould You Be Short on Vitamin D?AHA: New Report Emphasizes Safety of StatinsKidney Disease More Deadly for MenMore Illnesses From Tainted Romaine Lettuce ReportedMillions of Americans Still Breathing Secondhand Smoke: ReportKidney Disease Claiming More LivesHealth Tip: What to Do If You Suspect a ConcussionMany Americans Unaware of Promise of Targeted, 'Personalized' Medicine: PollAn App, Your Fingernail -- and Anemia Screening Is DoneAHA: Hearts From Unusual Donors Could Help Meet Growing Transplant DemandGene Therapy for Sickle Cell Takes Another Step ForwardFew Americans Have Optimal 'Metabolic Health'Most Americans Lie to Their Doctors1 in 10 Will Develop Eczema in Their LifetimeMany Cases of Polio-Like Illness in Kids May Be MisdiagnosedHealth Tip: Limit Exposure to BPAFirdapse Approved for Rare Autoimmune DisorderSecondhand Pot Smoke Can Harm an Asthmatic ChildAsian Longhorned Tick Is Invading United StatesNew Surgery Gets Amputee Moving Again -- Without the 'Phantom Limb' EffectClimate Change Ups Heat Deaths, Especially Among Elderly: ReportAHA: Infections May Be a Trigger for Heart Attack, StrokeWhat Couch Potatoes Don't Know Can Hurt ThemParkinson's Gene Therapy Wires New Brain CircuitsWhat's Best for Babies With Recurring Ear InfectionsNext for Disabling Back Pain? New Discs From Patients' Own CellsFreeze-Dried Vaccine May Help Rid World of PolioJust a Little Weightlifting Can Help Your HeartNerve Zap Might Ease Pain of Herniated DiskA 'Hypoallergenic' Dog? You May Be Barking Up the Wrong TreeAfter a Spouse's Death, Sleep Woes Up Health RisksMany Patients With Polyps Delay Follow-up Colonoscopy: StudyObesity Boosts Childhood Asthma Risk by 30 PercentHolidays a Challenge for Those With AllergiesWhat You Can Do to Prevent DiabetesAsk About the Antibiotics Prescribed for Your ChildNight Shift Plus Unhealthy Habits Equals Higher Diabetes RiskProbiotics Show No Effect on Kids' Tummy UpsetsSkin 'Glow' Test Might Someday Spot Disease Risk EarlyE. Coli-Tainted Romaine Lettuce Threatens the Frail, Sick MostHealth Tip: Caring for BronchitisDon't Eat Romaine Lettuce Due to E. Coli Outbreak, FDA WarnsObesity All on Its Own Can Raise Your Health Risks
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

First Drug Approved for Rare Eye Disease

HealthDay News
by -- Scott Roberts
Updated: Aug 23rd 2018

THURSDAY, Aug. 23, 2018 (HealthDay News) -- Oxervate (cenegermin) has been approved by the U.S. Food and Drug Administration to treat neurotrophic keratitis, a rare disease of the eye's cornea.

The cornea is the clear layer that covers the colored portion at the front of the eye.

Neurotrophic keratitis affects fewer than five in 10,000 people, the FDA said. The disease, causing loss of corneal sensation, leads to damage of this vital part of the eye.

"While the prevalence of neurotrophic keratitis is low, the impact of this serious condition on an individual patient can be devastating," Dr. Wiley Chambers, an ophthalmologist in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

Oxervate, produced as an eyedrop, was evaluated in a clinical study involving 151 people with neurotrophic keratitis. Some participants were given Oxervate, while others were given a placebo eye drop. Complete corneal healing was reported among 70 percent of people treated with Oxervate, compared with 28 percent of those given the placebo, the FDA said.

The most common side effects of the drug included eye pain, enlarged blood vessels in the eye, eye inflammation and watery eyes.

Oxervate is produced by the Italian firm Dompé farmaceutici.

More information

Visit the FDA to learn more.